Tradestie Institutional Equity Comparison Engine · Market Close Jul 24, 2026

RBOT.WS vs AVNS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVNS Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 10–0 Matrix Metrics)

AVNS Overall Winner 6-Pillar Tally: RBOT.WS 0 – 5 AVNS (1 Tie) Matrix Metrics: RBOT.WS 0 – 10 AVNS

As of Jul 24, 2026, Avanos Medical, Inc. (AVNS) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RBOT.WS carries a Unified Composite Score of 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas AVNS carries 56.7/100 (HOLD) at $24.99 (20.0x Forward P/E, 5.4% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RBOT.WS vs AVNS
RBOT.WS NYSE
Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.01
-24.77% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
50.1 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
AVNS NYSE Head-to-Head Winner
Avanos Medical, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$24.99
+0.04% 1D
Market Cap $1.2B
TTM Revenue $716M
Forward P/E 20.0x
Beta / 30D Vol 1.22β · 6% Vol
Unified Composite Score
56.7 / 100 HOLD
Tech 75.0 Fund 59.0 Flow 50.0 Mom 46.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.0 · SMA20: $24.93 · SMA50: $24.90

6-Pillar Scorecard Institutional Category Breakdown (RBOT.WS 0 – 5 AVNS)

Columns: Metric · RBOT.WS · AVNS
1. Valuation Multiples AVNS
Forward P/E N/M 20.0x
Trailing P/E N/M 30.7x
PEG Ratio N/M N/M
EV / Revenue N/M 1.6x
2. Growth & Scale AVNS
Revenue Growth (YoY) N/A +8.8%
Earnings Growth (YoY) N/A -21.7%
TTM Revenue (USD) N/A $716M
Market Cap N/A $1.2B
3. Profitability & Quality AVNS
Gross Margin N/A 50.0%
Operating Margin N/A 5.4%
Net Profit Margin N/A -10.4%
Return on Equity (ROE) N/A -9.2%
4. Balance Sheet & Cash Flow AVNS
Cash Generation (TTM) N/A $56M EBITDA
Cash Flow Margin N/A 7.8% EBITDA Mgn
Net Cash / Leverage N/A ROE $16.76 Book/Sh · -9.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 33.0% (50th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat AVNS
OpEx & R&D Intensity N/A 44.6% of Rev ($319M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RBOT.WS (0) vs AVNS (10)
Institutional Metric RBOT.WS AVNS Criterion Row Edge
Market Capitalization
Scale
N/A $1.2B Larger Scale AVNS
Trailing P/E Ratio
Valuation
N/M 30.7x Lower Multiple AVNS
Forward P/E Ratio
Valuation
N/M 20.0x Lower Multiple AVNS
Revenue Growth (YoY)
Growth
N/A +8.8% Higher Growth AVNS
Operating Margin (TTM)
Profitability
N/A 5.4% Higher Margin AVNS
Net Profit Margin
Profitability
N/A -10.4% Higher Margin AVNS
Return on Equity (ROE)
Capital Efficiency
N/A -9.2% Higher ROE AVNS
52-Week Range Position
Momentum
0% ($0–$0) 97% ($9–$25) Stronger Trend AVNS
Beta / 30D Volatility
Risk Regime
N/A 1.22β · 6% Vol Lower Realized Risk AVNS
Unified Institutional Score
Composite Signal
50.1 / 100 (HOLD) 56.7 / 100 (HOLD) Higher Composite AVNS
Trailing 12M Revenue (USD)
Operating Scale
N/A $716M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 50.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $56M EBITDA ($16.76 Book/Sh · -9.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVNS +76.29 pp
RBOT.WS: -67.2% · AVNS: +9.09%
3M Horizon AVNS +76.29 pp
RBOT.WS: -67.2% · AVNS: +9.09%
6M Horizon AVNS +76.29 pp
RBOT.WS: -67.2% · AVNS: +9.09%
1Y Horizon AVNS +76.29 pp
RBOT.WS: -67.2% · AVNS: +9.09%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RBOT.WS vs AVNS. Trailing 12-month operating profitability (RBOT.WS N/A vs AVNS 5.4%) and valuation multiples (RBOT.WS N/M vs AVNS 20.0x Forward P/E) are benchmarked directly in Pillar 4 below.

RBOT.WS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
AVNS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$716M
Gross Margin50.0%
Op. Margin5.4%
ROE / Fwd P/E-9.2% · 20.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RBOT.WS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RBOT.WS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVNS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 33.0%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVNS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RBOT.WS Moat Profile Cyclical / Execution-Driven Positioning
Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator
Competes within the Orthopedic, Prosthetic & Surgical Appliances & Supplies value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AVNS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.2B market capitalization and 5.4% operating margin.
OpEx & R&D Reinvestment 44.6% of Rev ($319M)
90D Engineering Disclosures 0 Published

Investor FAQ RBOT.WS vs AVNS Key Questions & Quantitative Answers

As of Jul 24, 2026, Avanos Medical, Inc. (AVNS) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RBOT.WS carries a Unified Composite Score of 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas AVNS carries 56.7/100 (HOLD) at $24.99 (20.0x Forward P/E, 5.4% operating margin). Technically, RBOT.WS sits in a Neutral phase (RSI N/A, UNCLASSIFIED options structure) and AVNS sits in a Neutral phase (RSI 57.0, UNCLASSIFIED options structure).

AVNS leads the Growth & Scale pillar: RBOT.WS posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with AVNS at +8.8% YoY revenue growth and -21.7% YoY earnings growth on $716M TTM revenue (50.0% gross margin, 5.4% operating margin). On trailing 12-month operating scale, RBOT.WS generates N/A in USD-normalized revenue versus $716M for AVNS. In operating R&D and SG&A reinvestment, RBOT.WS deploys N/A (0 90-day corporate R&D disclosures) versus 44.6% of Rev ($319M) (0 disclosures) for AVNS.

AVNS screens cheaper on headline valuation multiples. RBOT.WS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas AVNS trades at 20.0x Forward P/E, 30.7x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (7.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RBOT.WS (N/A ROE) versus AVNS (-9.2% ROE) capital efficiency.

In options market volatility and institutional positioning, RBOT.WS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, AVNS carries 33.0% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.22β · 6% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00 (RBOT.WS) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Jul 24, 2026. For educational research only; not investment advice.